Urogen Pharma Ltd URGN

$26.31 +1.56 (6.30%)

Valuation

Market cap
1,213,938,000
Revenue TTM
$109,790,000
Net income TTM
$-153,490,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-139.80%
Debt to equity
-1.43

Trading

Volume
1,493,000
Avg volume
1,043,338
Day's range
$24.72 – $26.84
Shares out
49,048,000
Stochastic %K
18%
Beta
1.68
Analysts
Strong Buy
Price target
$56.89

Price

Company profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a su...

Show more

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Phone
646 768 9780
Website
https://www.urogen.com
Address
400 Alexander Park Drive, 4th Floor, Princeton, United States

Latest news

No headlines yet.

Stocktwits

TradingLittlePharma Nov 10, 12:14 AM
$CPA will probably continue to climb after earnings, investors should expect tighter margins due to higher fuel prices and take that into account but we'll see. $KURA we're going up after earnings, I know it. $NU will rally back toward 16 after the overreaction due to the election in Brazil. $GRAB is losing steam, so I'm looking for a bull flag to start forming over the next 2 or 3 days. Lastly, $URGN is going to back up, easy peazy.
0 replies
SusQSmallMouth Nov 7, 1:19 AM
$URGN getting interesting. Eyeing that $20 range. I bought this June 2025 and sold at $24 after doubling my position. Launch still seems to be going solid. Spend and cash the main issue driving this down?
2 replies
chickenboy Nov 6, 9:06 PM
$URGN Its been a long and, and for many of us, disappointing week. Whether today was the bottom or just respite to even lower sp nobody knows. Get out and enjoy the weekend.
0 replies
GeniusLoci Nov 6, 6:24 PM 1 replies
chickenboy Nov 6, 5:50 PM
$URGN I just started to buy back in with 1K at 24.90. Looks like I should have waited a bit longer. GL.
0 replies
ybk1234 Nov 6, 5:42 PM
$URGN down down I want to add🙂🙂🙂
0 replies
ivocsev Nov 5, 5:08 PM
$URGN brutal. Still long term
1 replies
Mogeyman Nov 5, 3:30 PM
$URGN Stuck me like a pig with this one. Thanks URGN.
2 replies